Endothelium-Dependent Brachial Artery Flow Mediated Vasodilatation in Patients with Diabetes Mellitus With and Without Coronary Artery Disease

K Bhargava,* G Hansa,** M Bansal,* S Tandon,*** RR Kasliwal****

Abstract
Aim of the Study : Endothelial function as assessed by brachial artery flow mediated vasodilatation (FMD) has been shown to be impaired in patients with coronary artery disease (CAD). Since diabetes mellitus (DM) has been considered to be CAD risk-equivalent, we sought to determine whether endothelial dysfunction is present in patients with DM independent of presence of CAD.

Methodology : One hundred and ninety eight individuals were included in the study and divided into four groups: Group 1 - patients with risk factors for CAD, but no DM or CAD; Group 2 - patients with DM but no CAD; Group 3 - patients with CAD but no DM and Group 4 - patients with both DM and CAD. Brachial artery FMD assessment was performed once in all subjects and FMD was calculated as percentage increase in brachial artery diameter in response to increase in brachial artery flow.

Results : Mean FMD was significantly higher in Group 1 (7.03 ± 2.87%) compared to the other three groups. Mean FMD in Group 2 (5.51 ± 2.12%) was similar to that in Group 3 (4.56 ± 2.70%; p value 0.195) but significantly higher than that in Group 4 (4.26 ± 1.93%; p value 0.038). There was no statistically significant difference in mean FMD in Group 3 and Group 4 (p value 0.65).

Conclusion : Endothelial function as assessed by FMD is significantly impaired in diabetics compared to non-diabetics in absence of CAD. In addition, similar degree of impairment in endothelial function is seen in diabetics without CAD and non-diabetic patients having CAD, implying CAD risk-equivalence of diabetes.

INTRODUCTION
Endothelial dysfunction is a key early event in atherogenesis and is known to appear long before the formation of structural atherosclerotic changes. Assessment of endothelial function, thus, can provide valuable insight into pre-intrusive phase of atherosclerosis and can be used an early marker of future atherosclerotic disease. However, invasive nature of the earlier available tests for endothelial function assessment precluded their use in clinical practice. Development of non-invasive method of endothelial function assessment by brachial artery flow mediated vasodilatation (FMD), as described by Celermajer, provided an extremely useful tool for cardiovascular research and for clinical application. The test can be performed easily and has proven reproducibility. International Task Force on Brachial Artery Reactivity has recently laid guidelines for performance of FMD, thus standardizing the test for wider application.

Several studies have demonstrated endothelial dysfunction not only in patients with established coronary artery disease (CAD), but also in patients with cardiovascular risk factors including diabetes mellitus (DM). Since diabetes is now considered to be ‘CAD’ risk equivalent, we aimed to determine whether similar degree of impairment of endothelial function occurs in patients with DM and CAD that may be responsible for this ‘risk equivalence’.

METHODS
One hundred and ninety eight individuals were included in the study and divided into four groups. Groups 1 (n = 67) included subjects with risk factors for CAD, but no DM or CAD; Group 2 (n = 38) included patients with DM but no CAD; Group 3 (n = 58) included patients with CAD but no DM; and Group 4 (n = 35) included patients having both CAD and DM. Subjects in Group 1 and 2 were randomly selected from patients attending cardiology OPD of the Institute for routine checkup with no symptoms or signs of CAD. A negative treadmill test was used to confirm the

* Senior Resident; ** Attending Cardiologist; *** Junior Consultant; **** Senior Consultant and Head, Non-Invasive Cardiology, Escorts Heart Institute and Research Centre, New Delhi. Received : 3.12.2002; Accepted : 17.2.2003
considered to be a conventional risk factor. Current smoking or tobacco use in any form was before the age of 55 years in males and 65 years in females as positive if a first degree relative had a coronary event. Dyslipidemia was defined as LDL level ≤ 130 mg/dl, or HDL ≥ 40 mg/dl, or TG ≥ 200 mg/dl. Family history was coded as positive if a first degree relative had a coronary event before the age of 55 years in males and 65 years in female relatives. Current smoking or tobacco use in any form was considered to be a conventional risk factor.

The brachial artery FMD assessment was performed once in all subjects using 7.5 MHz phased array linear transducer attached to HP Sonos 5500 echocardiography machine. The test was done after overnight fasting. Smoking was prohibited for at least four hours before the test and all the vasoactive drugs such as nitrates were withheld for 48 hours preceding the test. The sphygmomanometer cuff was tied in the right arm with the patient in supine position. The brachial artery was imaged in the ante-cubital fossa and its diameter measured at end-systole. The systolic and diastolic VTIs (velocity time integrals) were also recorded using pulsed wave Doppler. The arm was then occluded with the sphygmomanometer cuff inflated to at least 50 mm Hg above systolic blood pressure for five minutes. The same measurements were repeated immediately (within 15 seconds) after release of the cuff. The brachial artery diameter was measured again at 1 minute to assess FMD. The ultrasound of the brachial artery was continuously recorded on the videotape before, during and up to two minutes after release of occlusion. The still images were also recorded on digital Enconcert system for post-procedure off-line analysis.

The flow in the brachial artery was calculated as

\[ \text{Baseline Flow} = \pi d_1^2/4 \times HR_1 \times (VTI_{S1} + VTI_{D1}) \]

where \( d_1 \) is brachial artery diameter, \( HR_1 \) is heart rate, \( VTI_{S1} \) is systolic VTI and \( VTI_{D1} \) is diastolic VTI at baseline.

\[ \text{Reactive Hyperemia Flow} = \pi d_2^2/4 \times HR_2 \times (VTI_{S2} + VTI_{D2}) \]

where \( d_2 \) is brachial artery diameter, \( HR_2 \) is heart rate, \( VTI_{S2} \) is systolic VTI and \( VTI_{D2} \) is diastolic VTI measured immediately after release of cuff.

Percentage increase in brachial artery flow was calculated as -

\[ \% \text{ Reactive hyperemia} = \left( \frac{\text{Reactive hyperemia flow} - \text{Baseline flow}}{\text{Baseline flow}} \right) \times 100 \]

FMD was calculated as -

\[ \text{FMD} = \left( \frac{d_2 - d_1}{d_1} \right) \times 100 \]

where \( d_2 \) is brachial artery diameter at 1 minute of cuff release.

**Statistical Analysis**

The statistical analysis was done of SPSS 10.0 for windows. All values were expressed as mean (standard deviation). The demographic data and risk factors were compared between the groups using chi-square and Student’s t test wherever appropriate. Unpaired Student’s t test was used to assess the presence of any difference in measured parameters in the four groups. A p value of <0.05 was considered as statistically significant.

**RESULTS**

The characteristics of the individuals in the four groups are as shown in Table 1. As is evident, subjects in all the four groups were age and sex matched. There was no significant difference in the incidence of conventional cardiovascular risk factors in any of the groups. However,
as was the study design, there was no diabetic in Group 1 and 3 whereas all the subjects in Group 2 and 4 had diabetes. Hence, the mean fasting and post-prandial blood glucose values (not shown) were higher in Groups 2 and 4 compared to those in Groups 1 and 3.

There was no significant difference in the brachial artery diameter and calculated brachial artery flow at baseline in the four groups (Table 2). During reactive hyperemia phase, similar degrees of increase in brachial artery flow were achieved in all the four groups. With the same degree of increase in brachial artery flow, significantly more marked flow mediated vasodilatation occurred at 1 minute in Group 1 (7.03 ± 2.87%) compared to the other three groups. FMD in Group 2 (5.51 ± 2.12%) was similar to that in Group 3 (4.56 ± 2.70%; p value 0.195) but significantly higher than that in Group 4 (4.26 ± 1.93%; p value 0.038). There was no statistically significant difference in mean FMD in Group 3 and Group 4 (p value 0.65) (Fig. 1).

**DISCUSSION**

Diabetes is associated with significantly increased rates of all forms of atherosclerotic disease including coronary artery disease.\textsuperscript{14-16} Multiple factors such as insulin resistance, metabolic abnormalities (e.g. hyperglycemia, dyslipidemia, elevated free fatty acid levels etc.), formation of advanced glycosylation end-products, hypertension, obesity, inflammation, all individually as well as interdependently contribute to early onset and accelerated progression of atherosclerosis in diabetes.\textsuperscript{17} The exact mechanisms involved in this are not entirely clear, however, endothelial dysfunction seems to play a key role. Many of the factors mentioned above can directly or indirectly result in endothelial dysfunction. Insulin itself has a direct vasodilatory effect mediated through nitric oxide,\textsuperscript{18} an effect that has been shown to be impaired in patients with DM.\textsuperscript{19}

Compelling data now exists to suggest that endothelial dysfunction occurs in both type\textsuperscript{19,11} and type 2\textsuperscript{12} diabetes as well as in subjects with insulin resistance without diabetes.\textsuperscript{20} Clarkson et al in their study showed FMD to be significantly impaired in diabetics as compared to controls (5.0 ± 3.7% vs. 9.3 ± 3.8%; p <0.001) and the degree of impairment was directly related to the duration of diabetes.\textsuperscript{9} Similarly Yu HI et al also found FMD to be significantly impaired in diabetics as compared to controls.\textsuperscript{12} The impairment was more marked

| Table 2: Comparison of measured parameters of FMD assessment in the study groups |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                | Group 1         | Group 2         | Group 3         | Group 4         |
| Baseline diameter (mm)*        | 3.853 ± 0.459   | 3.733 ± 0.729   | 3.800 ± 0.434   | 3.797 ± 0.670   |
| Baseline flow (ml/min)*        | 129.2 ± 81.2    | 131.3 ± 71.5    | 130.5 ± 90.6    | 108.9 ± 47.5    |
| Reactive hyperemia flow (ml/min)* | 522.3 ± 283.2  | 457.6 ± 175.2   | 437.2 ± 234.0   | 399.9 ± 212.9   |
| % hyperemia*                   | 326.3 ± 198.8   | 294.7 ± 165.1   | 293.0 ± 218.5   | 282.9 ± 169.9   |
| FMD (%)**                      | 7.025 ± 2.87    | 5.506 ± 2.12    | 4.558 ± 2.70    | 4.258 ± 1.93    |

FMD - Flow mediated vasodilation; *All the p values for comparison between the groups > 0.05; **p values for FMD in Group 1 and 2 - 0.035; Group 1 and 3 - < 0.0001; Group 1 and 4 - < 0.0001; Group 2 and 3 - 0.195; Group 2 and 4 - 0.038; Group 3 and 4 - 0.650
in those diabetics who had associated peripheral arterial disease. Dogra et al showed FMD to be impaired in diabetics even in presence of near-normoglycemia and normoalbuminuria. As was in the study by Yu HI et al, here again FMD impairment was more marked if diabetic complication was also present (microalbuminuria in this case). In the present study, we have also observed significant impairment of FMD in diabetics as compared to controls. Our data, thus, is in agreement with the results of the previous studies.

In addition, we found similar degree of FMD impairment in diabetics without CAD and CAD patients not having diabetes. Though, as per our knowledge, no study has attempted similar comparison, several authors have shown equally increased cardiovascular morbidity and mortality in diabetics without CAD and non-diabetics with CAD. Haffner et al in their follow up study found seven year incidence of cardiovascular mortality to be 20.2% in diabetics without prior myocardial infarction and 18.8% in non-diabetics with prior myocardial infarction (p value >0.4). Since, endothelial dysfunction has already been shown to be a good predictor of future risk of cardiovascular events, our study, by demonstrating equal impairment of FMD in patients with DM alone and in patients with CAD alone, indicates this to be the likely mechanism underlying equally increased risk of cardiovascular morbidity and mortality in these two groups. However, large population-based studies are needed to confirm these findings. Additionally, whether varying impairment in FMD in patients with DM will provide incremental value in risk stratification for future cardiovascular events need to be evaluated in large prospective studies.

References